Balchem Co. (NASDAQ:BCPC) has received an average recommendation of “Hold” from the six analysts that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $122.33.
BCPC has been the subject of a number of research analyst reports. BidaskClub cut Balchem from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 29th. HC Wainwright began coverage on Balchem in a report on Tuesday, September 25th. They set a “buy” rating for the company. Sidoti raised Balchem from a “neutral” rating to a “buy” rating and set a $127.00 price objective for the company in a report on Tuesday, October 16th. ValuEngine raised Balchem from a “hold” rating to a “buy” rating in a report on Thursday, August 30th. Finally, Pivotal Research raised Balchem from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $95.00 to $100.00 in a report on Tuesday.
Balchem stock opened at $90.12 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.42 and a quick ratio of 2.82. Balchem has a 12-month low of $70.23 and a 12-month high of $117.79. The stock has a market capitalization of $2.94 billion, a P/E ratio of 35.62 and a beta of 0.97.
Balchem (NASDAQ:BCPC) last released its quarterly earnings results on Tuesday, November 6th. The basic materials company reported $0.73 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.61 by $0.12. Balchem had a return on equity of 14.51% and a net margin of 15.67%. The business had revenue of $155.04 million during the quarter, compared to analysts’ expectations of $163.66 million. During the same period in the previous year, the business posted $0.63 earnings per share. The firm’s revenue for the quarter was up 2.9% compared to the same quarter last year. As a group, sell-side analysts predict that Balchem will post 2.45 EPS for the current fiscal year.
A number of large investors have recently made changes to their positions in BCPC. Zeke Capital Advisors LLC bought a new stake in Balchem during the 2nd quarter worth about $203,000. Cubist Systematic Strategies LLC bought a new stake in shares of Balchem in the 2nd quarter valued at about $218,000. Granahan Investment Management Inc. MA bought a new stake in shares of Balchem in the 2nd quarter valued at about $224,000. Bbva Compass Bancshares Inc. bought a new stake in shares of Balchem in the 3rd quarter valued at about $226,000. Finally, Sigma Planning Corp bought a new stake in shares of Balchem in the 2nd quarter valued at about $229,000. 88.48% of the stock is owned by hedge funds and other institutional investors.
Balchem Company Profile
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry.
Featured Article: Understanding Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.